These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 21815074)

  • 1. Measurement of proteasomal dysfunction in cell models of dopaminergic degeneration.
    Sun F; Kanthasamy AG; Kanthasamy A
    Methods Mol Biol; 2011; 758():293-305. PubMed ID: 21815074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. α-mangostin derivative 4e as a PDE4 inhibitor promote proteasomal degradation of alpha-synuclein in Parkinson's disease models through PKA activation.
    Chen JY; Zhu Q; Cai CZ; Luo HB; Lu JH
    Phytomedicine; 2022 Jul; 101():154125. PubMed ID: 35525236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The pattern of neuronal loss and survival may reflect differential expression of proteasome activators in Parkinson's disease.
    McNaught KS; Jnobaptiste R; Jackson T; Jengelley TA
    Synapse; 2010 Mar; 64(3):241-50. PubMed ID: 19924695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Environmental neurotoxic chemicals-induced ubiquitin proteasome system dysfunction in the pathogenesis and progression of Parkinson's disease.
    Sun F; Kanthasamy A; Anantharam V; Kanthasamy AG
    Pharmacol Ther; 2007 Jun; 114(3):327-44. PubMed ID: 17521740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of ubiquitin linkages on alpha-synuclein induced-toxicity in a Drosophila model of Parkinson's disease.
    Lee FK; Wong AK; Lee YW; Wan OW; Chan HY; Chung KK
    J Neurochem; 2009 Jul; 110(1):208-19. PubMed ID: 19457126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reprint of: revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease-resemblance to the effect of amphetamine drugs of abuse.
    Perfeito R; Cunha-Oliveira T; Rego AC
    Free Radic Biol Med; 2013 Sep; 62():186-201. PubMed ID: 23743292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ubiquitin-proteasome system and Parkinson's diseases.
    Betarbet R; Sherer TB; Greenamyre JT
    Exp Neurol; 2005 Feb; 191 Suppl 1():S17-27. PubMed ID: 15629758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early-onset impairment of the ubiquitin-proteasome system in dopaminergic neurons caused by α-synuclein.
    McKinnon C; De Snoo ML; Gondard E; Neudorfer C; Chau H; Ngana SG; O'Hara DM; Brotchie JM; Koprich JB; Lozano AM; Kalia LV; Kalia SK
    Acta Neuropathol Commun; 2020 Feb; 8(1):17. PubMed ID: 32059750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of Protein Ubiquitination by Paraquat and 1-Methyl-4-Phenylpyridinium Impairs Ubiquitin-Dependent Protein Degradation Pathways.
    Navarro-Yepes J; Anandhan A; Bradley E; Bohovych I; Yarabe B; de Jong A; Ovaa H; Zhou Y; Khalimonchuk O; Quintanilla-Vega B; Franco R
    Mol Neurobiol; 2016 Oct; 53(8):5229-51. PubMed ID: 26409479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lycorine, a natural alkaloid, promotes the degradation of alpha-synuclein via PKA-mediated UPS activation in transgenic Parkinson's disease models.
    Zhu Q; Zhuang XX; Chen JY; Yuan NN; Chen Y; Cai CZ; Tan JQ; Su HX; Lu JH
    Phytomedicine; 2021 Jul; 87():153578. PubMed ID: 34038839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Natural alkaloid harmine promotes degradation of alpha-synuclein via PKA-mediated ubiquitin-proteasome system activation.
    Cai CZ; Zhou HF; Yuan NN; Wu MY; Lee SM; Ren JY; Su HX; Lu JJ; Chen XP; Li M; Tan JQ; Lu JH
    Phytomedicine; 2019 Aug; 61():152842. PubMed ID: 31048127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ubiquitin proteasome system in Parkinson's disease: a keeper or a witness?
    Martins-Branco D; Esteves AR; Santos D; Arduino DM; Swerdlow RH; Oliveira CR; Januario C; Cardoso SM
    Exp Neurol; 2012 Dec; 238(2):89-99. PubMed ID: 22921536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Parkinson's disease-related protein DJ-1 protects dopaminergic neurons in vivo and cultured cells from alpha-synuclein and 6-hydroxydopamine toxicity.
    Batelli S; Invernizzi RW; Negro A; Calcagno E; Rodilossi S; Forloni G; Albani D
    Neurodegener Dis; 2015; 15(1):13-23. PubMed ID: 25500798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intersecting pathways to neurodegeneration in Parkinson's disease: effects of the pesticide rotenone on DJ-1, alpha-synuclein, and the ubiquitin-proteasome system.
    Betarbet R; Canet-Aviles RM; Sherer TB; Mastroberardino PG; McLendon C; Kim JH; Lund S; Na HM; Taylor G; Bence NF; Kopito R; Seo BB; Yagi T; Yagi A; Klinefelter G; Cookson MR; Greenamyre JT
    Neurobiol Dis; 2006 May; 22(2):404-20. PubMed ID: 16439141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alpha-synuclein aggregation, Ubiquitin proteasome system impairment, and L-Dopa response in zinc-induced Parkinsonism: resemblance to sporadic Parkinson's disease.
    Kumar V; Singh D; Singh BK; Singh S; Mittra N; Jha RR; Patel DK; Singh C
    Mol Cell Biochem; 2018 Jul; 444(1-2):149-160. PubMed ID: 29198021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel 1-hydroxypyridin-2-one metal chelators prevent and rescue ubiquitin proteasomal-related neuronal injury in an in vitro model of Parkinson's disease.
    Lewis FW; Fairooz S; Elson JL; Hubscher-Bruder V; Brandel J; Soundararajan M; Smith D; Dexter DT; Tétard D; Pienaar IS
    Arch Toxicol; 2020 Mar; 94(3):813-831. PubMed ID: 32078022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence for dopaminergic axonal degeneration as an early pathological process in Parkinson's disease.
    O'Keeffe GW; Sullivan AM
    Parkinsonism Relat Disord; 2018 Nov; 56():9-15. PubMed ID: 29934196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteasome inhibition modeling nigral neuron degeneration in Parkinson's disease.
    Xie W; Li X; Li C; Zhu W; Jankovic J; Le W
    J Neurochem; 2010 Oct; 115(1):188-99. PubMed ID: 20649845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteasome impairment by α-synuclein.
    Zondler L; Kostka M; Garidel P; Heinzelmann U; Hengerer B; Mayer B; Weishaupt JH; Gillardon F; Danzer KM
    PLoS One; 2017; 12(9):e0184040. PubMed ID: 28945746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protein degradation pathways in Parkinson's disease: curse or blessing.
    Ebrahimi-Fakhari D; Wahlster L; McLean PJ
    Acta Neuropathol; 2012 Aug; 124(2):153-72. PubMed ID: 22744791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.